Chlamydia pneumoniae and atherosclerosis - What we know and what we don't

Clinical Microbiology and Infection

Volumn 8, Issue 1, 2002, Pages 2-13

  Ngeh, J ^a   Anand, V ^a   Gupta, S ^a,b  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Infection; Inflammation

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; AZITHROMYCIN; ERYTHROMYCIN; HOMOCYSTEINE; MACROLIDE; METHIONINE; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TETRACYCLINE;

ABDOMINAL AORTA ANEURYSM; AMINO ACID METABOLISM; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEROEPIDEMIOLOGY; STROKE; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALIA; BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; HELICOBACTER; HELICOBACTER PYLORI;

EID: 0036038494     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2002.00382.x     Document Type: Article

References (131)

1. Mortality by cause for eight regions of the world: Global burden of disease study
2. Atherosclerosis-An inflammatory disease
3. Infectious causes of atherosclerosis
4. Chronic infection, Chlamydia and coronary heart disease
5. Chronic infection in the aetiology of atherosclerosis-focus on Chlamydia pneumoniae
6. Chlamydia pneumoniae and atherosclerosis: Causal or coincidental link?
7. Plaque disruption and thrombosis: Potential role of inflammation and infection
8. Inflammation, infection and antimicrobial therapy in coronary heart disease - Where do we currently stand?
9. Impact of viral and bacterial infectious burden on longterm prognosis in patients with coronary artery disease
10. Atherosclerosis involves more than just lipids: Focus on inflammation
11. Chlamydia pneumoniae, monocyte activation and antimicrobial therapy in coronary heart disease
12. Inflammation and infection in coronary artery disease
13. Chlamydia, Pneumoniae in Elderly Patients with Stroke Study (CPEPS): A case-control study on the seroprevalence of Chlamydia pneumoniae in patients aged over 65 years admitted with acute stroke or transient ischaemic attack
14. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections
15. Chlamydia pneumoniae sp. nov. for Chlamydia sp. Strain TWAR
16. Current knowledge on Chlamydia pneumoniae, strain TWAR, an important cause of pneumonia and other acute respiratory diseases
17. Chlamydia pneumoniae
18. Chlamydia pneumoniae and the lung
19. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families. 1966-79
20. The epidemiology and significance of Chlamydia pneumoniae
21. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae
22. Chlamydia pneumoniae (TWAR)
23. Seroprevalence of Chlamydia pneumoniae in elderly stroke and medical patients: A case-control study
24. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)
25. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR
26. Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in CAD patients
27. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
28. Association of Chlamydial infection with cerebrovascular disease
29. Background and current knowledge of Chlamydia pneumoniae in atherosclerosis
30. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: Large prospective study
31. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
32. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms
33. Antibodies against Chlamydia pneumoniae predict the need for elective surgical intervention on small abdominal aortic aneurysms
34. Chlamydia pneumoniae serology: Importance of methodology in patients with coronary heart disease and healthy individuals
35. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma - Evaluation of the innocent bystander hypothesis
36. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques
37. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors
38. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection
39. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease
40. Detection of C pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction
41. Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells
42. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques
43. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries
44. Histological and ultrastructural findings suggesting an initiating role for Chlamydia pneumoniae in the pathogenesis of atherosclerosis: A study of fifty cases
45. Chlamydia pneumoniae in arteries: The facts, their interpretation, and future studies
46. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma - Evaluation of the innocent bystander hypothesis
47. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual
48. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis
49. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease
50. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen
51. Demonstration of viable Chlamydia pneumoniae in atherosclerotic plaques of carotid arteries by reverse transcriptase polymerase chain reaction
52. The role of Chlamydia pneumoniae in atherosclerosis - Recent evidence from animal models
53. Rabbit models for Chlamydia pneumoniae infection
54. Chlamydia pneumoniae induces inflammatory changes in the aortas of rabbits
55. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
56. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice
57. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae
58. Mouse models of Chlamydia pneumoniae infection
59. Preclinical models for Chlamydia pneumoniae and cardiovascular disease: Hypercholesterolaemic mice
60. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae
61. Provocation of experimental aortic inflammation and dilatation by inflammatory mediators and Chlamydia pneumoniae
62. Chlamydia pneumoniae antigens cause experimental aortic dilatation: An effect counteracted by azithromycin
63. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice
64. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice
65. Chlamydia pneumoniae multiplies in human endothelial cells in vitro
66. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae
67. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells
68. In vitro infection of smooth muscle cells by Chlamydia pneumoniae
69. Adhesion molecules: II. Blood vessels and blood cells
70. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response
71. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The atherosclerosis risk in communities (ARIC) study
72. Fibrinogen. C-reactive protein, albumin, or white cell count: Meta-analyses of prospective studies of coronary heart disease
73. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes
74. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
75. For the cholesterol and recurrent events (CARE) investigators. Elevation of tumor necrosis factor alpha and increased risk of recurrent coronary events after myocardial infarction
76. Heart disease and the inflammatory response
77. Chlamydia pneumoniae and coronary heart disease: Coincidence, association or causation?
78. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link?
79. Chlamydia pneumoniae facilitates monocyte adhesion to endothelial and smooth muscle cells
80. Infection as a cause of CHD
81. Chlamydia pneumoniae and atherosclerosis: Links to the disease process
82. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes
83. Induction of macrophage foam cell formation by Chlamydia pneumoniae
84. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae
85. Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes
86. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae
87. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation
88. Chlamydia heat shock protein 60 localises in human atheroma and regulates macrophage tumour necrosis factor-α and matrix metalloproteinase expression
89. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces TF and PAI-1 expression: A potential link to accelerated arteriosclerosis
90. Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells
91. Chlamydia pneumoniae activates nuclear factor κB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation
92. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction
93. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
94. Chlamydia pneumoniae, monocyte activation and azithromycin in coronary heart disease
95. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS Study
96. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study
97. Antibiotics and risk of subsequent first-time acute myocardial infarction
98. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction
99. Randomised secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Infection with Chlamydia (ACADEMIC) Study
100. Randomised secondary prevention trial of azithromycin in patients with CAD: Primary clinical results of the ACADEMIC Study
101. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial
102. Randomised double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion
103. Anti-inflammatory effects of macrolide antibiotics
104. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes
105. Anti-inflammatory activity of clarithromycin in adults with chronically inflammed sinus mucosa
106. Doxycycline inhibition of aneurysmal degeneration in an elastase induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase
107. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis
108. Antibiotic therapy in coronary heart disease - Where do we currently stand?
109. Infections and coronary heart disease: Potential for new therapies?
110. Chlamydia pneumoniae and myocardial infarction (CLAINF). Preliminary randomised controlled study with clarithromycin CLAINF Protocol
111. A review of Chlamydia pneumoniae and atherosclerosis
112. Treating cardiovascular disease with antimicrobial agents: A survey of knowledge, attitudes, and practices among physicians in the United States
113. Arterites infectieuses experimentales
114. Experimental artertis and arteriosclerosis associated with streptococcal inoculations
115. Ultrastructural changes in cardiac capillaries of Coxsackie B4-infected mice
116. Virus-induced cholesterol crystals
117. Pathogensis studies in experimental mycoplasma disease: M gallisepticum infections of turkeys
118. Virus-induced atherosclerosis
119. Nucleic acid sequence of cytomegalovirus in cells cells cultured from human arterial tissue
120. Herpes simplex virus infection in human arterial cells. Implications in arteriosclerosis
121. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infraction
122. Influence of the measles virus on the proliferation and protien synthesis of aortic endothelial and smooth muscle cells
123. Coronary disease in patients after heart transplantation
124. Coronary lesions and immunodeficiency virus infection
125. Relation of Helicobacter pylori infection and coronary heart disease
126. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications
127. Long term vascular complications of Coxiella burnetti infection in Switzerland: Cohort study
128. Multiple infections in carotid atherosclerotic plaques
129. Identification of periodontal pathogens in atheromatous plaques
130. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis
131. Association of influenza vaccination and reduced risk of recurrent myocardial infarction